Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
zanidatamab zovodotin (ZW49) / Zymeworks
NCT03821233: A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers	Completed	1	112	Canada, US, RoW	ZW49	Zymeworks BC Inc.	HER2-expressing Cancers	09/24	10/24
JRCT2031210161: A Study of Zanidatamab in Japanese Subjects With Locally Advanced or Metastatic HER2-Expressing Cancers	Recruiting	N/A	48	Japan	zanidatamab zovodotin (ZW49) - Zymeworks	Zymeworks BC Inc.	Locally advanced (unresectable) and/or metastatic HER2-expressing cancer; cancer